Urgent Need for U.S. Drug Manufacturing Shift from China, Says Sen. Banks

During a recent policy event, Sen. Jim Banks (R-Ind.) emphasized the pressing need for the United States to shift its drug manufacturing away from China, citing lessons learned from the coronavirus pandemic. He raised a critical question regarding the current Secretary of Health and Human Services, Robert F. Kennedy Jr.: how does the U.S. address the fact that a significant portion—30 to 40 percent—of its manufacturing is based in a country considered its biggest adversary?

Banks conveyed to Breitbart News that the pandemic highlighted the necessity of removing as much manufacturing from China as possible. He noted, “What we’ve learned from the coronavirus is that this situation cannot continue.”

He expressed concerns about how China exploits legal loopholes to benefit itself at the expense of American companies, like Eli Lilly, and inundates the U.S. market with cheap, potentially dangerous ingredients and GLP-1 formulations—like Ozempic. “It’s not America First,” he declared.

On a brighter note, Banks pointed out that the Health and Human Services and the Food and Drug Administration (FDA) have a dedicated team ready to tackle this issue.

Last October, he urged the FDA to enhance its scrutiny of foreign drug manufacturers amid rising alarm over the quality of drugs produced overseas, particularly from China and India.

In a letter to the FDA Commissioner, Dr. Marty McCulley, Banks argued that more needs to be done to safeguard America’s drug supply and highlighted the problem of low-quality foreign manufacturing and unethical domestic operations that import drugs from these sources. Alarmingly, 39% of facilities with FDA import alerts are in China; 13% are in India, compared to an average of only 10% from other regions. In fiscal year 2024, the FDA inspected just 28% of facilities in China and 33% in India that produce drugs for the U.S. market. Among those inspected, Indian manufacturers had a notably high violation rate for Good Manufacturing Practices at 13%.

A coalition of federal and state officials, including members from the National Association of Attorneys General and Congress, is pushing for increased FDA oversight of online sellers of compounded GLP-1 receptor antagonists and unregulated active pharmaceutical ingredients (APIs).

At the same event, Sen. Tom Cotton (R-Ark.) also advocated for legislation aimed at bringing drug manufacturing back to American soil, highlighting the extensive reliance on China for active pharmaceutical ingredients. For example, China supplies about 95% of ibuprofen imports and 70% of acetaminophen used in U.S. medicines.

Moreover, a report from Axios indicated that the coronavirus pandemic jeopardizes the U.S. supply of around 150 medications, including essential antibiotics and both generic and brand-name drugs, with some lacking any market substitutes.

Banks reiterated concerns regarding how China manipulates legal structures to gain advantages, exacerbating risks to American health. “This situation must change; it’s simply not in our best interest,” he stated firmly.